CMLEU23033 // A042001 // O'Dwyer
Basic Study Information
Purpose:
This phase II trial compares the combination of inotuzumab ozogamicin and chemotherapy
to the usual chemotherapy in treating patients with B-cell acute lymphoblastic leukemia
or B-cell lymphoblastic lymphoma. Inotuzumab ozogamicin is a monoclonal antibody,
called inotuzumab, linked to a drug, called CalichDMH. Inotuzumab is a form of targeted
therapy because it attaches to specific molecules (receptors) on the surface of cancer
cells, known as CD22 receptors, and delivers CalichDMH to kill them. Chemotherapy
drugs work in different ways to stop the growth of cancer cells, either by killing
the cells, by stopping them from dividing, or by stopping them from spreading. Giving
inotuzumab ozogamicin with chemotherapy may help shrink the cancer and stop it from
returning.
Location: University of Rochester
Lead Researcher (Principal Investigator)
Lead Researcher:
Kristen O'Dwyer
Study Contact Information
Study Contact: Clinical Trials Office
Study Location: Wilmot Cancer Institute, University of Rochester Medical Center
Study Email: WCICTOResearch@urmc.rochester.edu
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search